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Abstract
Obesity is an increasing public health problem, with two-thirds of the adult population in many Western countries
now being either overweight or obese. Male obesity is associated with late onset hypogonadism, a condition
characterised by decreased serum testosterone, sperm quality plus diminished fertility and quality of life. In this
paper we propose a novel theory underlying the development of obesity related hypogonadism- the GELDING
theory (Gut Endotoxin Leading to a Decline IN Gonadal function).
Several observational studies have previously reported an association between obesity related hypogonadism (low
testosterone) and systemic inflammation. However, for the first time we postulate that the trans-mucosal passage of
bacterial lipopolysaccharide (LPS) from the gut lumen into the circulation is a key inflammatory trigger underlying
male hypogonadism. Obesity and a high fat/high calorie diet are both reported to result in changes to gut bacteria
and intestinal wall permeability, leading to the passage of bacterial endotoxin (lipopolysaccharide- LPS) from within
the gut lumen into the circulation (metabolic endotoxaemia), where it initiates systemic inflammation. Endotoxin is
known to reduce testosterone production by the testis, both by direct inhibition of Leydig cell steroidogenic
pathways and indirectly by reducing pituitary LH drive, thereby also leading to a decline in sperm production.
In this paper we also highlight the novel evolutionary benefits of the GELDING theory. Testosterone is known to be
a powerful immune-suppressive, decreasing a man’s ability to fight infection. Therefore we postulate that the male
reproductive axis has evolved the capacity to lower testosterone production during times of infection and resulting
endotoxin exposure, decreasing the immunosuppressive influence of testosterone, in turn enhancing the ability to
fight infection. While this response is adaptive in times of sepsis, it becomes maladaptive in the setting of
“non-infectious” obesity related metabolic endotoxaemia.
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Résumé
L’obésité est un problème de santé publique en expansion ; les deux-tiers de la population adulte de nombreux
Pays de l’Ouest sont actuellement soit en surpoids, soit obèses. L’obésité masculine est associée à l’hypogonadisme
de survenue tardive, une situation caractérisée par un taux abaissé de testostérone, une qualité spermatique réduite
ainsi qu’une diminution de la fertilité et de la qualité de vie. Dans le présent article, nous proposons une nouvelle
théorie sous-tendant le développement de l’hypogonadisme lié à l’obésité – la théorie GELDING (Gut Endotoxin
Leading to a Decline IN Gonadal function ; Endotoxines intestinales donnant lieu à un déclin de la fonction
gonadique).
Plusieurs études observationnelles ont précédemment rapporté une association entre hypogonadisme (testostérone
basse) lié à l’obésité et inflammation systémique. Toutefois, nous postulons pour la première fois que le passage
trans-muqueuse de lypopolysaccharides bactériens (LPS) de la lumière intestinale dans la circulation constitue un
élément inflammatoire clé déclencheur de l’hypogonadisme masculin. L’obésité et une alimentation riche en
graisse/riche en calories sont toutes deux signalées pour induire des modifications des bactéries intestinales et de
la perméabilité de la paroi intestinale, conduisant au passage d’endotoxines bactériennes (lipopolysaccharide- LPS)
de l’intérieur de la lumière intestinale dans la circulation (endotoxémie métabolique) où elles initient une
inflammation systémique. Les endotoxines sont connues pour réduire la production de testostérone par les
testicules, à la fois par inhibition directe des voies de la stéroïdogenèse des cellules de Leydig et indirectement par
la réduction du pic de LH hypophysaire, ce qui conduit aussi à une réduction de la production de spermatozoïdes.
Dans le présent article, nous avons aussi mis en relief nouveaux bénéfices évolutionnaires de la théorie GELDING. La
testostérone est connue pour être un puissant immunosuppresseur qui diminue la capacité d’un homme à
combattre l’infection. Par conséquent, nous postulons que l’axe reproducteur masculin a élaboré la capacité à
diminuer la production de testostérone pendant les périodes d’infection et d’exposition aux endotoxines qui en
résulte, ce qui réduit ainsi l’influence immunosuppressive de la testostérone, et en retour augmente la capacité de
combattre l’infection. Alors que cette réponse est adaptée en période de sepsis, elle devient inadaptée dans le
cadre de l’endotoxémie métabolique ‘non infectieuse’ liée à l’obésité.
Mots clés: Hypogonadisme masculin, Testostérone, Endotoxine, Lipopolysaccharide (LPS), Microbiome intestinal
Introduction
Obesity and its impact on male reproductive health
Obesity has become an increasing public health concern
over the last few decades, primarily due to an increase in
the availability of calorie dense processed food and the
adoption of a sedentary lifestyle. A recent review of body
mass index (BMI) changes in 199 countries reported that
20 % of the world population have a BMI above the ideal
range (25 kg/m2), with a total of 205 million men being
obese (BMI ≥ 30 kg/m2) [1]. In developed countries such
as the United States of America, one-third of the popu-
lation are known to be overweight and a further third is
obese [1]. As obesity is a known risk factor for the devel-
opment of significant general health concerns such as
diabetes, cardiovascular disease, osteoarthritis, poor
mental health and early death [2], this increase in obesity
is of major public health concern.
In the last decade increasing evidence has also emerged
linking obesity with impaired male reproductive health,
producing so called late-onset male hypogonadism [3].
Obesity related hypogonadism is characterised by low
serum testosterone levels and associated symptoms such
as poor libido, erectile dysfunction, depression, lack of
motivation, lethargy; as well as somatic symptoms such as
muscle weakness, aches and pains [3]. These symptoms
can have a major impact on men’s quality of life, especially
when they affect relatively young men in their 30’s and
40’s. Furthermore, as testosterone is known to maintain
muscle, obesity related hypogonadism produces a decline
in muscle mass and therefore basal metabolic rate, mean-
ing that these men burn fewer calories at rest and exercise,
predisposing them to gaining further fat - a detrimental
positive feedback loop.
Obesity has also been linked with impaired sperm
production and function. Recent meta-analyses have
linked obesity with a significant increased risk of low
sperm count, motility and morphology, plus an increase
in sperm DNA fragmentation, resulting in a decline in
fertility potential [4, 5]. This decline in sperm quality
with increasing BMI may help explain the gradual
decrease in the general population’s sperm quality,
particularly sperm count, which has been observed to
coincide with the increasing trend in obesity over the
last few decades [6, 7].
Given the very significant reproductive and general
health concerns related to obesity, new approaches to
managing this growing epidemic need to be found.
While improving diet and increasing exercise are known
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to reverse weight gain and normalise reproductive hor-
mones [8–10], very few patients are capable of adhering
to these lifestyle changes over the long term, resulting in
no long term improvements in body composition. How-
ever, if it were possible to reverse the decline in serum
testosterone associated with obesity, this would not only
improve men’s reproductive function and quality of life,
but also result in an increase in their lean body mass
(muscle) and an increase in their basal metabolic rate
[11], producing a sustained reduction in fat mass.
Current theories behind obesity related male
hypogonadism
The current prevailing theory behind obesity related
hypogonadism is that the decline in testosterone levels is
due to a combination of reduced pituitary LH drive
(central hypogonadism) and a direct impairment of
testicular function (peripheral hypogonadism) [3, 6].
Adipose tissue contains abundant aromatase activity, an
enzyme responsible for the conversion of testosterone to
estrogen, with 80 % of male estrogen being derived from
the action of aromatase [12]. Therefore, an increase in
adipose tissue aromatase results in an increase in the
conversion of testosterone to estrogen, reducing serum
testosterone levels. Furthermore, estrogen has a “nega-
tive feedback” influence on the hypothalamic pituitary
(HP) axis resulting in a decrease in anterior pituitary LH
pulse frequency and amplitude [3, 6]. Since LH is the
prime stimulus for increasing testicular Leydig cell pro-
duction of testosterone, this estrogen related reduction
in LH drive further produces a drop in testosterone
production. Blocking aromatase action with letrazole (an
aromatase inhibitor) has been reported to result in an
increase in LH and testosterone concentration in obese
men [13].
White adipose tissue is a major endocrine organ that
secretes over 30 biologically active peptides and proteins
such as leptin and immunomodulatory cytokines such as
TNFα and IL-6 [6]. Under lean conditions leptin in-
creases LH and FSH release by a direct stimulatory
effect on the anterior pituitary, and via increasing hypo-
thalamic GnRH pulsatility [14]. However, in obesity
leptin levels significantly increase which then results in a
functional state of leptin resistance, with impaired leptin
action and a resultant decline in HP axis function. Simi-
larly, the pro-inflammatory adipocytokines TNFα and
IL-6 have also been reported to impair HP axis function
and subsequent testosterone production [6, 15]. There-
fore, increased production of estrogen by aromatase,
combined with the direct inhibition of the HP axis by
leptin and adipose derived inflammatory cytokines, re-
sults in a central hypogonadal state.
There is also abundant evidence linking obesity with a
direct impairment of testicular function. INSL3, a
hormone produced by the Leydig cells independent of
pituitary LH drive, has been reported to be negatively as-
sociated with BMI, providing evidence for obesity
directly impairing Leydig cell function independent of
the HP axis [16]. Similarly, levels of inhibin B [17] and
AMH [18], both products of the Sertoli cells of the
testis, have been reported to decline with increasing
BMI, which suggest that obesity also directly impairs
Sertoli cell function. Again leptin may play a key role in
obesity related testicular dysfunction as leptin has been
shown to inhibit the Leydig cell’s production of testos-
terone [14, 19].
Obesity is known to be characterised in an increase in
the production of reactive oxygen species (ROS) and as-
sociated oxidative stress, both systemically [20] and
within sperm themselves [21]. It is also well established
that oxidative stress can impair sperm production and
function [22], and there is evidence linking oxidative
stress with impaired Leydig cell function [22, 23]. There-
fore testicular oxidative stress is also likely to play a
significant role in obesity related male hypogonadism.
Finally, morbid obesity is associated with the enveloping
of the scrotal contents in pelvic fat tissue, which impedes
heat transfer compared to the lean scenario where the
testis hang free of the body within the scrotum, maintain-
ing a temperature 2 °C below core body temperature. This
adipose related “heating” of the testicles is likely to signifi-
cantly impair sperm production, since spermatogenesis is
optimally performed at 35 °C [24].
The GELDING theory for obesity related male
hypogonadism
Gelding A castrated animal; - usually applied to a
horse, but formerly used also of the human male.
(Webster’s Dictionary).
The GELDING hypothesis
In the GELDING theory of male late onset hypogonad-
ism we hypothesise that obesity, and its associated poor
diet (high fat and high calorie), causes a breakdown in
the normal intestinal mucosal barrier function (so called
“leaky gut”), that then facilitates the passage of gut
bacteria from the bowel lumen into the systemic circula-
tion. Here powerful immune stimulants present in bac-
teria such as endotoxin elicit a chronic state of low
grade inflammation (metabolic endotoxaemia) through-
out the body that in turn impairs testicular function and
reproductive performance (Fig. 1). The GELDING the-
ory of obesity related male hypogonadism is entirely
novel, since currently there is no direct evidence linking
obesity, metabolic endotoxaemia and impaired testicular
function. However, several lines of evidence support the
plausibility of this theory.
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Obesity, “leaky gut” and resultant chronic inflammation
from metabolic endotoxaemia
The central key to the GELDING theory of male hypo-
gonadism is that activation of the immune system by an
obesity related trigger is then capable of impairing tes-
ticular function. Several large epidemiological studies
have already reported an association between male obes-
ity, markers of inflammation such as CRP and white cell
count (WCC), and a reduction in serum testosterone
[25–28]. As testosterone is known to be immune-
suppressive [29, 30], this association between obesity
related inflammation and lower levels of serum testoster-
one has previously been suggested to be caused by a
reduction in testosterone’s immune-suppressive action
[26]. However, observational studies are incapable of
proving cause and effect, nor the mechanistic direction
of such associations. Therefore we contend that the
reduction in testosterone’s immune-suppressive effect is
not the underlying cause of increased inflammation seen
in obese men, but rather the reverse. Specifically, obesity
triggers an inflammatory response that in turn impairs
testicular function, and that this results in both a
reduction in testosterone production and impaired
spermatogenesis.
There is mounting evidence that obesity and a high in
fat/calorie diet may provide a gut bacteria derived trigger
for initiating inflammation throughout the body. The
human gut contains nearly 2 kg, or 100 trillion (1014)
bacteria, a population that outnumbers the body’s own
eukaryotic cells by a 10-fold order of magnitude [31].
The bacterial density of the gut is relatively low in the
proximal portion of the gastrointestinal tract (stomach,
small intestine) due to the inhibitory effects of stomach
acid and bile on bacterial growth, but reaches very large
numbers (1012 CFU per gram faecal material) in the
colon [31]. Many species of gut bacteria such as bifido-
bacteria and lactobacillus actually provide a beneficial
symbiotic role to the human host, such as processing
insoluble dietary fibre into short chain fatty acids that
can be utilised by the host’s intestinal mucosa as an en-
ergy source, or the production of key vitamins such as
Vitamin B12 and Vitamin K [31]. However, other bacter-
ial species such as gram negative bacteria have clear
pathogenic capacity, with the presence of such a huge
number of bacteria within the body posing a significant
potential threat to the host’s health.
The mucosal surface of the gastrointestinal tract
covers an area equivalent to the size of a tennis court,
allowing for the very efficient transfer of food and water
from the gut lumen into the circulation. However, this
also provides a large area of susceptibility for points of
entry of harmful gut bacteria into the systemic circula-
tion, where they can initiate activation of the body’s
immune system and even overwhelming sepsis. Fortu-
nately the trans-mucosal passage of gut bacteria is nor-
mally prevented by several mucosal barrier defence
mechanisms, including the production of a thick mucus
lining that repels bacteria from the intestinal surface,
Fig. 1 An overview of the GELDING theory of obesity related male hypogonadism
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bactericidal antibodies and immune proteins, as well as
tight junctions between the epithelial cells that ideally
prevent passage of macro-molecules like endotoxin or
intact bacteria between epithelial cells [32, 33].
Obesity, and a diet high in fat or calories that is typic-
ally consumed by obese individuals, has been reported
to cause a breakdown in the normal mucosal barrier
function, leading to the passage of gut bacteria into the
systemic circulation, initiating a chronic state of inflam-
mation [34, 35]. Gram negative bacteria, which comprise
70 % of the total bacterial load in the human gut [36],
contain a potent immune stimulant in their cell wall re-
ferred to as lipopolysaccharide (LPS) or endotoxin. Ani-
mal experiments and human observational studies have
shown that consumption of diets containing either high
fat or high number of calories leads to significant
changes in gut bacterial populations and increases in the
circulating levels of plasma endotoxin [37, 38], implying
a breakdown in gut mucosal wall integrity and the pas-
sage of gram negative bacteria into the systemic circula-
tion. Interestingly, the magnitude of this “metabolic
endotoxaemia” is reported to be more pronounced in
mice placed on a high fat diet than an isocaloric high
carbohydrate diet, suggesting that dietary fat is more ef-
ficient in transporting bacterial endotoxin from the gut
lumen into the circulation, possibly mediated by transfer
of endotoxin across the intestinal wall in lipid laden chy-
lomicrons [34, 38]. Furthermore, a high fat diet is
reported to unfavourably alter the gut microbial
composition, leading to an increase in intestinal perme-
ability due to disordered tight junction proteins (zonulin,
occludin) [39], and a reduction in the colonic mucous
barrier [40]. Confirming the importance of gut micro-
biome in facilitating endotoxaemia, the administration of
antibiotics to obese mice or modification of their gut
microbiome with prebiotic fibre, have both been
reported to result in a decline in circulating plasma
endotoxin levels [39, 41, 42].
Cross-sectional studies in humans have also reported
an elevation in circulating levels of endotoxin [38, 43,
44], or indirect markers of endotoxin (LBP) exposure
[45, 46], in obese individuals. Obesity has also been
shown to be associated with changes in the human gut
microbiome, with several investigators now reporting a
reduction in the beneficial genus bifidobacterium in the
faecal samples of obese individuals [47, 48]. Since bifido-
bacterium are known to metabolise dietary fibre, produ-
cing short chain fatty acids (SCFA) that “feed” the host
intestinal mucosa, and enhance the production of mucus
and maintain tight junction barrier function [49], it is
likely that any reduction in bifidobacterium numbers
due to obesity will result in a breakdown in intestinal
barrier function and endotoxaemia. Furthermore, obese
men have also been shown to have a more marked post-
prandial endotoxaemic and inflammatory (IL-6)
response to a standard meal containing 40 gm of fat
than their age matched lean counterparts [34, 50]. As
such, we propose that changes in the intestinal micro-
biome caused by obesity, and the associated “poor diet”,
result in a breakdown in the mucosal barrier function of
the gut (so called “leaky gut”), and that this results in
the passage of gram negative bacteria into the circulation
(metabolic endotoxaemia) which triggers a chronic state
of inflammation that impairs testicular function.
Endotoxin and impaired testicular function
Currently there is no experimental data supporting a dir-
ect link between endotoxin exposure in the male and
impaired testosterone production or spermatogenesis.
However, studies in women have confirmed an associ-
ation between endotoxaemia and a reduction in the
ovaries capacity to produce the female sex steroid
hormone progesterone [46]. Furthermore, there is abun-
dant animal evidence suggesting that endotoxin (LPS)
does have the capacity to impair testicular function.
Firstly, the experimental administration of LPS to rats,
sheep, cattle and non-human primates has been shown
to decrease the frequency and amplitude of LH pulses
by suppressing both hypothalamic and anterior pituitary
function [51], thereby reducing the pituitary drive for
Leydig cells to produce testosterone. Secondly, animal
studies have also confirmed that Leydig cells express the
TLR4 for endotoxin [52], and that experimental admin-
istration of LPS directly inhibits Leydig cell production
of testosterone [52–57]. The direct inhibition of andro-
gen production by endotoxin is most likely mediated by
a reduction in Leydig cell expression of steroidogenic
acute regulatory (StAR) protein activity [58], a protein
that plays a key role in the initial transfer of cholesterol
into mitochondria where it is later converted into
testosterone.
The activation status of testicular macrophages is
also likely to play a role in testosterone production.
Leydig cells and macrophages are normally in close
physical contact within the testicular interstitium, and
under normal conditions these macrophages play a
key role in Leydig cell development as they provide
essential growth and differentiation factors [58]. How-
ever, under immune-stimulatory conditions, as occurs
with metabolic endotoxaemia, macrophages produce
pro-inflammatory cytokines such as IL-1 and TNFα,
plus reactive oxygen species (ROS), all known to
reduce steroid hormone production by the adjacent
Leydig cell [55, 57, 58]. Furthermore, Leydig cells
themselves have been reported to produce inflammatory
cytokines (IL-1β, TNFα and IL-6) when exposed to LPS
[52], which would result in a further amplification of the
neighbouring macrophages state of activation. Interestingly,
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dampening inflammation using TNFα blocking antibody
therapy has been shown to normalise serum testosterone
levels in spondylo-arthritis patients [59], highlighting the
potential role for inflammation in decreasing testosterone
production.
Endotoxin and impaired sperm function
Obesity related endotoxaemia is likely to impair
sperm production and function, both directly and
indirectly. Firstly, high intra-testicular levels of testos-
terone are required for normal sperm production. In-
adequate levels of testosterone disturbs Sertoli cell
function, leading to retention and phagocytosis of
mature spermatids [60] and impaired epididymal
function, both potentially reducing sperm number and
quality. Secondly, human sperm have been reported
to express both the TLR4 [61] and the CD14 co-
receptor for LPS [62], as well as directly responding
to LPS exposure by increasing their production of IL-
6 [63], initiating sperm apoptosis and a decline in
sperm motility [61, 64–66]. Furthermore, as semen is
known to contain both LPS and leukocytes [61], it is
not surprising that endotoxin exposure would increase
seminal leukocyte reactive oxygen species (ROS) pro-
duction and result in sperm oxidative damage [67,
68]. Seminal plasma neopterin, a marker of macro-
phage activation status, has been reported to be
increased in obese men [69], with seminal plasma
neopterin also being positively correlate with sperm
oxidative stress, DNA damage and apoptosis [69].
This finding, together with previous publications link-
ing impaired sperm production with an increase in
testicular macrophage density [70, 71], all support the
concept that a trigger for inflammation such as meta-
bolic endotoxaemia has the potential to impair spermato-
genesis and sperm function.
The evolutionary advantages associated with
GELDING theory of endotoxin suppression of
testicular function
In today’s environment of abundant high-calorie food
and a resulting epidemic of obesity, it would appear
that the GELDING concept of inflammatory mediated
suppression of testicular function is maladaptive; with
the resulting decline in testosterone production lead-
ing to a reduction in lean muscle mass and further
predisposing to adiposity. However, outside of the context
of the modern industrialised society, we believe that in-
flammatory suppression of testicular function may actually
be an adaptive response, helping protect men from sepsis
and preventing them from passing on their genes in times
of sickness.
Testosterone, immune responses and the immune-
competence handicap
Testosterone is known to exert a suppressive effect on
both humoral and cellular immune responses, and there-
fore appears to provide a natural anti-inflammatory
advantage to men outside times of infection. Testoster-
one is reported to dampen the immuno-stimulatory
activity of monocytes, macrophages, NK cells, T lympho-
cytes, as well as reducing antibody production by B lym-
phocytes [29]. As a result, autoimmune diseases such as
systemic lupus erythematosus (SLE), rheumatoid arth-
ritis, systemic sclerosis and myasthenia gravis are all sig-
nificantly less common in men than women [30].
Conversely, men with androgen deficiency are at in-
creased risk of autoimmune disease; with Sjogren
syndrome, rheumatoid arthritis, autoimmune hypo-
throidism and SLE all being more common in hypo-
gonadal men with Klinefelter’s Syndrome than their
androgen replete counterparts [72]. Interestingly, many
Klinefelter’s Syndrome patients with SLE experience a
significant decline in their lupus activity once they com-
mence androgen replacement therapy [73], highlighting
the potent immune-suppressive actions of testosterone.
While testosterone may provide men with an auto-
immune advantage, it also limits their capacity to fight
infections, thereby resulting in increased rates of infec-
tious morbidity and mortality compared to women [74,
75]. Folstad and Karter [76] were first to propose the
concept of male “immunocompetence handicap”; a situ-
ation where males are required to balance the competing
demands of high testosterone production for optimal re-
productive performance (sperm production, develop-
ment of male secondary sexual characteristics attractive
to females and the maintenance of assertive territorial
behaviour conducive to successful mating), with this
“cost” of high testosterone being diminished immune
capacity and susceptibility to infection. For example,
dominant “alpha” male reindeers, baboons and chimpan-
zees, known to possess both the highest levels of testos-
terone and reproductive performance, also have been
reported to have the greatest parasitic infective load
compared with non-dominant or castrated males [76–
78]. Interestingly, castration of dominant males has the
ability to reduce their susceptibility to these types of
parasitic infections [79], while experimental treatment
with high dose testosterone increases the intensity of
parasitic infection and resultant mortality [80, 81].
What constitutes the optimal adaptive balance
between high testosterone levels and reproductive per-
formance, versus lower testosterone levels and resistance
to infection, depends on the longevity of the animal and
its social behaviour. Australian marsupials such as the
dasyurid (quoll) have evolved a semelparious, or so
called “big-bang” suicidal reproductive behaviour, where
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a male engages in a single frenzied mating season in
their entire life fuelled by high testosterone levels, but
then dies shortly after mating from infection brought
about by a total collapse in their immune system [82–
84]. In an environment with limited food resources, and
where the male plays no active role in the upkeep of his
progeny, this type of semelparous reproductive strategy
may actually be adaptive since it enables him to pass on
his genes, while not competing for limited resources
with his offspring. However, the optimal balance be-
tween high testosterone and reproductive performance
and immunity is likely to be very different for humans.
Firstly, men are expected to play an active role in sup-
porting their children over a number of years, with the
death of a father having a major detrimental effect on
their children’s welfare. As such, high immune compe-
tence and longevity are of paramount importance to
men and their families. Secondly, for most part humans
reproduce in a monogamous setting, where males do
not need to compete with other males for an opportun-
ity to “mate”, unlike the animal world where males
require high testosterone to develop body strength and
aggressive behaviour in order to defend their territory
and attract a female mate. Therefore, the human male
only requires sufficient testosterone to maintain normal
spermatogenesis, but not supra-physiological levels that
will unnecessarily suppress his immune system and
potentially compromise his survival.
The ability for an infection to reduce testosterone pro-
duction, thereby removing this hormonal brake on infec-
tion fighting capacity, is supported by the available
literature. Several animal studies using experimental
administration of endotoxin (LPS) as a surrogate for sep-
sis has shown that endotoxin initiated inflammation is a
powerful inhibitor of testosterone production [52–57].
Similar studies in men have reported that endotoxin
does suppress the production of the adrenal androgen
DHEA [85], although no study to date has reported the
effect of experimental administration of endotoxin on
testosterone levels. However, a prospective study of 28
men has reported a significant reduction in serum tes-
tosterone and an elevation in estrogen during times of
severe sepsis [86], a pattern identical to what we have
proposed to occur in obese males as a result of meta-
bolic endotoxaemia. While the magnitude of endotoxae-
mia in sepsis is approximately 10-50 fold higher than
that seen in obesity [35], we still believe that it is reason-
able to conclude that chronic exposure to low grade
endotoxinaemia may interfere with testosterone produc-
tion, in support of the GELDING theory.
Testosterone, infection and “reproductive fitness”
Male fertility has been shown to transiently decline
during times of infection, with a significant reduction in
sperm count, motility, morphology and DNA integrity
[87–90], plus a reduction in sperm fertilising capacity all
being reported [91]. Previously it has been postulated
that these reductions in sperm quality were due to an
elevation in core body temperature (fever) that com-
monly occurs during infection, since spermatogenesis is
optimal at 35 °C [24]. However, chronic low grade infec-
tions with Hepatitis B and HIV have also been reported
to cause a reduction in sperm quality, without any
change in body temperature [92, 93]. Interestingly,
around 25 % of young to middle-aged men chronically
infected with HIV have hypogonadism and androgen
deficiency [94], with the reduction in their sperm quality
being directly proportional to the severity of their infec-
tious load (CD4+ count) [93]. As such, it appears highly
probable that chronic infection and its associated
inflammatory response are capable of impairing testicu-
lar function and producing a drop in sperm quality and
testosterone production. While we acknowledge that
viral and parasitic infections do not result in exposure of
the host to LPS, an immune stimulant exclusively found
in gram negative bacteria, these observations do support
the GELDING hypothesis as they provide evidence that
an inflammatory stimulus (viral, parasitic or bacterial
exposure) can result in impaired testicular function.
From an evolutionary perspective, it is obvious that a
male who is unhealthy due to infection should ideally
not be capable of siring offspring. Firstly, sickness may
signify a poor genetic endowment (propensity to illness),
a characteristic that is best not passed on to the next
generation. Secondly, since infection has been linked
with a reduction in sperm DNA integrity [88, 90], and
poor sperm DNA quality has been linked with an in-
creased risk of miscarriage and illness in the resultant
offspring [95], a block in the capacity of unhealthy males
to reproduce makes perfect evolutionary “Darwinian”
sense. The decline in sperm quality with infection pro-
vides the ideal biological roadblock preventing such
conceptions.
A second roadblock to unhealthy males reproducing is
the observed reduction in libido and social withdrawal.
The experimental replication of infection through ad-
ministration of endotoxin (LPS) to men has been re-
ported to produce depression, anxiety, fatigue and a
sense of social disconnection [96], so called “sickness be-
haviour”. Of course all of these psychological symptoms
are likely to significantly reduce the probability of a
sexual encounter and successful reproduction. While no
study to date has directly analysed the link between the
administration of endotoxin to men, the onset of sick-
ness behaviour and changes in serum testosterone, it is
highly probable that these symptoms are at least in
part due to an acute suppression in testosterone pro-
duction. Firstly, the sickness behaviours associated
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with experimental administration of endotoxin (de-
creased mood, fatigue, social disconnection, anhedo-
nia) very closely resemble the psychological symptoms
associated with androgen deficiency [3, 96]. Secondly,
animal models of sickness behaviour using experimen-
tal administration of endotoxin report that male
behaviour can be normalised by co-administration of
testosterone therapy [97], highlighting the role of an-
drogen deficiency in endotoxin mediated sickness be-
haviours. In the setting of infection, a decline in
activity and social interest is adaptive since it allows
the body to rest and recover, while also reducing the
chance of spreading the infection to others. However,
in the setting of obesity related metabolic endotoxae-
mia the chronic adoption of sickness behaviour (al-
tered mood, poor motivation, and social isolation) is
clearly maladaptive. As such, more research is needed
to investigate the potential links between obesity, meta-
bolic endotoxaemia, and impaired testicular function plus
potential treatments for this significant malady.
Novel therapies to combat obesity related
impairment of gonadal function
Current treatments for impaired reproductive function in
obese men
Current therapies for male hypogonadism primarily
address the symptoms of androgen deficiency by initiat-
ing testosterone replacement therapy, rather than treat-
ing the underlying pathology (testicular inflammation).
While androgen therapy can be very effective at revers-
ing the psychological and physical symptoms of andro-
gen deficiency [3], it also inhibits spermatogenesis, often
causing azoospermia [98]. Therefore traditional andro-
gen replacement therapy is unable to treat both aspects
of obesity related hypogonadism -low testosterone and
subfertility.
Weight loss through diet and exercise is reported to
result in a significant improvement in testosterone levels
[8–10], however sustained weight loss over a long dur-
ation is accomplished by only a minority of obese men.
Bariatric surgical procedures are known to be more ef-
fective in producing long term weight loss than diet and
exercise alone [99], and several investigators have now
reported improvements in obese men’s sex hormone sta-
tus [100–103], plus semen quality [104] with this type of
surgical approach. Furthermore, one study did report a
significant decline in inflammation (serum CRP) and a
corresponding increase in testosterone following weight
loss surgery [100], but unfortunately failed to analyse the
correlation between these two outcomes, nor did they
measure changes in endotoxin exposure. Finally it
should be recognised that bariatric surgery is not with-
out its risks, and therefore other less invasive alternative
therapies are still needed.
Modification of the intestinal microbiome in order to
treat obesity related hypogonadism
According to the GELDING theory of hypogonadism,
the key to effective treatment of androgen deficiency
and impaired fertility in obese men is to improve the
barrier function of the intestine, thereby preventing
trans-migration of bacteria from the bowel lumen into
the systemic circulation through a leaky gut wall. The
resultant reduction in metabolic endotoxaemia would
improve testicular function both directly and indirectly
through increased pituitary LH drive.
Therapies directed at changing the resident bowel flora
(microbiome) have recently gained interest as potential
treatments for improving human health. This is achieved
by either administration of probiotic bacterial supple-
ments, or prebiotic supplements that nourish beneficial
bowel bacteria. A probiotic is defined as “a live micro-
organism which when administered in adequate amounts
confers a health benefit to the host” [105]. Probiotics are
often referred to as “good” or “beneficial bacteria” since
they limit the growth of “bad” bacteria like endotoxin con-
taining gram negative bacteria. The two most commonly
used probiotic organisms are bifidobacterium and lactoba-
cillus, since both of these bacteria are non-pathogenic and
known to enhance gut health [105].
Probiotic bacteria may help prevent metabolic endo-
toxaemia through two distinct mechanistic pathways.
Firstly these beneficial bacteria reduce the intestinal load
of potentially harmful gram negative bacteria by inhibit-
ing the growth of these bacteria through lowering co-
lonic pH, competing for nutrients and enhancing the
secretion of antibacterial immunoglobulins and bacteri-
cidal compounds by the intestinal mucosa [32, 33]. Sec-
ondly, probiotic bacteria are capable of producing short
chain fatty acids (SCFA) which “feed” the adjacent intes-
tinal wall, increasing the health and barrier function of
the mucosal surface [49]. SCFA have been reported to
increase the production of mucous by goblet cells within
the colonic wall, thereby providing a physical barrier that
reduces contact with bacteria in the gut lumen, minimis-
ing the potential for trans-migration of these bacteria
into the systemic circulation. In addition, SCFA derived
from beneficial bacteria are known to enhance the pro-
duction of epithelial tight junction proteins that prevent
passage of macromolecules such as endotoxin between
intestinal epithelial cells [49].
Prebiotics are best described as a selective food source
for beneficial “good” bacteria, or as “a selectively fer-
mentable ingredient that allows specific changes, both in
the composition and/or activity in the gastrointestinal
microflora that confers benefits upon host wellbeing and
health” [105]. In order for a substance to be considered
prebiotic it must not be digestible by the host, instead
being delivered relatively intact to the colonic lumen
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where it may act as nutrients for beneficial bacteria. Sec-
ondly, the prebiotic substance must support the growth
and function of beneficial bacteria such as bifidobacter-
ium and lactobacillus, while not facilitating the growth
of non-beneficial “bad” bacteria. Currently the long
chain fructo-oligosaccharide inulin, present in wheat,
onion, bananas, garlic, asparagus and artichoke, is the
most commonly ingested prebiotic. However, as these
foods contain only relatively small amounts of inulin,
most prebiotic supplements contain inulin soluble fibre
derived from the processing of chicory root. Frequently,
the most effective manner of improving the gut micro-
biome is the combined application of probiotics with
prebiotic- so called symbiotic therapy [105].
Currently there is significant animal experimental evi-
dence suggesting that the use of probiotic therapy can
improve the intestinal wall barrier function and result in
a reduction in levels of endotoxaemia [106]. Administra-
tion of the probiotic bacteria akkermansia mucinophilia
to mice has been reported to enhance the colon’s mu-
cous barrier and result in a drop in systemic endotoxin
levels [40]. Similarly, the use of lactobacillus probiotic
therapy in mice has been reported to increase the intes-
tines production of barrier function occludin and
claudin-1 tight junction proteins [107], and decrease gut
permeability [108], thereby resulting in a reduction in
systemic endotoxin exposure [107, 109]. Furthermore, a
recent randomised controlled trial reported a significant
reduction in inflammation (high sensitivity CRP levels)
in obese adults given a 3 month probiotic supplement
containing bifidobacterium [110], although it is uncer-
tain if this reduction was mediated by a decline in meta-
bolic endotoxaemia, or whether these changes translated
into improvements in serum testosterone.
Animal studies have now provided the first evidence
supporting the ability of probiotic supplements to boost
testicular function in obese subjects. In one study, the
consumption of a probiotic mixture containing lactoba-
cillus and other probiotic bacteria by rats fed a high fat
diet was reported to be able to prevent sperm oxidative
stress and the associated reduction in sperm quality
[111]. Similarly, another group noted that male mice fed
a diet containing the probiotic bacteria lactobacillus reu-
teri had larger testicles, greater Leydig cell density and
higher serum testosterone and increased spermatogen-
esis compared to controls [112]. Interestingly, in order
to test whether the beneficial effects of the L. reuteri
probiotic were associated with an anti-inflammatory
mechanism, these investigators administered antibodies
that blocked the action of the pro-inflammatory cytokine
IL-17. Those mice depleted of IL-17 activity were found
to have greater testicular volume and higher Leydig and
germ cell density compared to sham treated controls,
similar to what was also observed in the L. reuteri
treated males, thereby supporting the conclusion that L.
reuteri probiotic most probably prevents aged related de-
cline in testicular function by dampening inflammation.
Future research directions
Going forward, several studies need to be conducted in
order to support or refute the GELDING hypothesis.
Firstly, we personally anticipate conducting observa-
tional studies examining the relationship between serum
testosterone and estrogen, semen quality, various mea-
sures of adiposity (BMI, waist circumference, percentage
body fat) and levels of endotoxin exposure. We antici-
pate that endotoxin exposure will be negatively associ-
ated with both serum testosterone and sperm quality. In
addition, it would also be interesting to correlate direct
measures of intestinal permeability, such as sugar ab-
sorption tests [113], with changes in testicular function.
Secondly, as observational studies can never prove caus-
ation themselves, we would like to see if the experimen-
tal administration of endotoxin (LPS) to healthy men
does result in changes in serum testosterone, estrogen
and sperm production. These types of “low dose endo-
toxaemia” studies have already been conducted by many
investigators in the fields of cardiovascular and behav-
ioural science [85, 114], with endotoxin exposure being
well tolerated by participants, yet no study to date has
measured the impact of endotoxin exposure on male re-
productive function. Interestingly, a recent study which
randomised men to an infusion of the pro-inflammatory
cytokine IL-2 or saline placebo, did confirm that initi-
ation of a systemic state of inflammation did result in a
significant reduction in serum testosterone [115]. Fur-
thermore, if our GELDING theory of obesity related
hypogonadism is supported by the experiments outlined
above, then we believe that it would be prudent to com-
mence trials examining ways in which modification of
gut permeability may improve testicular function. Here
the use of pre and probiotic supplements to modify the
gut microbiome and enhance intestinal barrier function
appears to be an obvious initial therapeutic choice for
augmenting testicular function in obese men. Any
therapy that can reverse hypogonadism in obese men is
likely to significantly improve their quality of life
(increased energy and sexual function, improved mood
and motivation), but also may produce weight loss by
increasing activity and muscle mass, leading to a reduc-
tion in the incidence of cardiovascular disease and other
obesity related medical conditions. Finally, as endotoxin-
related inflammation is associated with insulin resist-
ance, type 2 diabetes mellitus and cardio-vascular
disease [37, 41–45, 114], new therapeutic approaches
that improve gut barrier function producing a reduction
in endotoxaemia and inflammation may also reduce
these types of metabolic diseases [35, 110]. These are
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certainly worthwhile research goals to investigate in the
future.
As with most diseases, we acknowledge that obesity
related male hypogonadism is likely to have several
underlying triggers, with metabolic endotoxaemia play-
ing one significant role in the disease patho-physiology.
It is almost certain that other processes unrelated to
endotoxin or inflammation, such as adipose tissues con-
version of testosterone to estrogen and the resulting
negative feedback on the HP axis, also play significant
roles in impairing testicular function. The purpose of
this paper is to inform the scientific community of the
role that gut derived endotoxin has as one of many po-
tential causes of obesity related hypogonadism.
Conclusions
While we acknowledge that currently there is no human
data directly linking endotoxin exposure to impaired tes-
ticular function, we still believe that there is considerable
circumstantial evidence supporting such a theory. Firstly,
obesity and a high fat diet have both been conclusively
linked with changes in gut microbiota, increased intes-
tinal permeability and the resultant leakage of bacterial
endotoxin from the gut lumen into the systemic circula-
tion (metabolic endotoxaemia) [38, 43–46]. Secondly,
animal studies have clearly shown that exposure to
endotoxin does result in a reduction in testosterone pro-
duction, both indirectly (impaired pituitary LH drive),
and through direct inhibition of Leydig cell function
[51–57]. While similar studies have not yet been con-
ducted in men, it has been reported that serum testos-
terone levels do fall during times of infectious endotoxin
exposure [86], as anticipated by the GELDING theory.
Furthermore, multiple large observational studies have
now linked increased levels of inflammation (raised CRP
and WCC) with lower serum testosterone [25–28].
The GELDING theory is entirely novel in that for the
first time it provides a clue to what may be initiating in-
flammation and impairing testicular function in obese
men- gut derived endotoxin. If proven correct, the
GELDING theory opens up a whole new scope for treat-
ment of the hypogonadal male through modification of
his gut microbiome and intestinal permeability. For ex-
ample, obesity related hypogonadism becomes more
common with increasing age, causing significant physical
and psychological impairment. However, modification of
the gut microbiome using probiotics has already been
reported to reverse this age-related hypogonadism in ro-
dents [112], raising exciting therapeutic potential for
older men.
Finally, the GELDING theory poses the interesting and
important evolutionary concept that endotoxin related
suppression of testicular function may originally have
been an adaptive response in times of sepsis (removing
testosterone mediated immunosuppression, preventing
sick males reproducing). However, such a response in to-
day’s world of food abundance is now more commonly
maladaptive, where “non-infectious” metabolic endotox-
aemia related androgen deficiency significantly reduces
obese men’s fertility and quality of life.
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